Compare
Insmed Inc vs Opko Health, Inc. vs TG Therapeutics, Inc. vs Axsome Therapeutics, Inc.
| Latest fiscal year | Insmed Inc INSM | Opko Health, Inc. OPK | TG Therapeutics, Inc. TGTX | Axsome Therapeutics, Inc. AXSM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $606.42M | $606.88M | $616.29M | $638.50M |
| Revenue growth (YoY) | +66.7% | -14.9% | +87.3% | +65.5% |
| Gross margin | 79.7% (computed) | 33.9% | 83.7% (computed) | n/a |
| Operating margin | -205.6% | -19.3% | 20.0% | -26.1% |
| Net margin | -210.5% | -37.2% | 72.6% | -28.7% |
| Net income | -$1.28B | -$225.68M | $447.18M | -$183.17M |
| EPS (Diluted) | -$6.42 | -$0.30 | $2.77 | -$3.68 |
| Operating cash flow | -$935.01M | -$178.54M | -$24.77M | -$93.41M |
| Free cash flow | -$967.58M | -$190.82M | -$24.99M | -$93.89M |
| Cash & equivalents | $510.44M | $364.41M | $79.15M | $322.93M |
| Total assets | $2.26B | $1.93B | $1.06B | $689.80M |
| Total liabilities | $1.53B | $663.99M | $415.23M | $601.51M |
| Shareholders' equity | $738.98M | $1.27B | $648.02M | $88.30M |
| Return on year-end equity | -172.8% | -17.8% | 69.0% | -207.5% |
| Shares outstanding | 214.26M | n/a | 155.31M | 50.88M |
Revenue, most recent five fiscal years
| Fiscal year | Insmed Inc | Opko Health, Inc. | TG Therapeutics, Inc. | Axsome Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $606.42M Ended 2025-12-31 | $606.88M Ended 2025-12-31 | $616.29M Ended 2025-12-31 | $638.50M Ended 2025-12-31 |
| 1 year earlier | $363.71M Ended 2024-12-31 | $713.14M Ended 2024-12-31 | $329.00M Ended 2024-12-31 | $385.69M Ended 2024-12-31 |
| 2 years earlier | $305.21M Ended 2023-12-31 | $863.50M Ended 2023-12-31 | $233.66M Ended 2023-12-31 | $270.60M Ended 2023-12-31 |
| 3 years earlier | $245.36M Ended 2022-12-31 | $1.00B Ended 2022-12-31 | $2.79M Ended 2022-12-31 | $50.04M Ended 2022-12-31 |
| 4 years earlier | $188.46M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $6.69M Ended 2021-12-31 | n/a |